United Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1996-01-01
- Employees
- -
- Market Cap
- $15.5B
- Website
- http://www.unither.com
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients with ESRD
- Conditions
- ESRD (End-Stage Renal Disease)Kidney TransplantationXenotransplantation
- Interventions
- Biological: 10 GE Xenokidney
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT06878560
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Conditions
- Pulmonary HypertensionPulmonary Hypertension Due to Lung Diseases and HypoxiaInterstitial Lung Disease
- Interventions
- Other: Prospective study assessments
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 1000
- Registration Number
- NCT06388421
- Locations
- 🇺🇸
Ascension St. Vincent, Indianapolis, Indiana, United States
🇺🇸NCH Research Institute, Naples, Florida, United States
🇺🇸Intercoastal Medical Group, Sarasota, Florida, United States
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Conditions
- Progressive Pulmonary FibrosisInterstitial Lung Disease
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 698
- Registration Number
- NCT05943535
- Locations
- 🇺🇸
UAB Lung Health Center, Birmingham, Alabama, United States
🇺🇸Norton Thoracic Institute, Phoenix, Arizona, United States
🇺🇸Peter Morton Medical Building, Los Angeles, California, United States
Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
- Conditions
- Interstitial Lung DiseasePulmonary Hypertension
- Interventions
- Procedure: Right heart catheterization (RHC)
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT05776225
- Locations
- 🇺🇸
Renown Regional Medical Center, Reno, Nevada, United States
🇺🇸Pulmonary Associates, Phoenix, Arizona, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
- Conditions
- Interstitial Lung DiseaseIdiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 597
- Registration Number
- NCT05255991
- Locations
- 🇵🇪
Hospital de Chancay y Servicios Basicos deSalud, Huaral, Lima, Peru
🇵🇪Clinica Ricardo Palma, Lima, Peru
🇵🇪Hospital Central de la Fuerza Aerea Del Peru, Lima, Peru
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Parenteral Treprostinil
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 52
- Registration Number
- NCT05203510
- Locations
- 🇺🇸
Banner University Medical Center (University of Arizona), Phoenix, Arizona, United States
🇺🇸HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, United States
🇺🇸University of California San Francisco - Fresno, Fresno, California, United States
Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Combination Product: Remunity Pump for Remodulin
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT05060315
- Locations
- 🇺🇸
Syneos Health, Morrisville, North Carolina, United States
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary FibrosisInterstitial Lung Disease
- Interventions
- Device: Treprostinil Ultrasonic Nebulizer
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 792
- Registration Number
- NCT04905693
- Locations
- 🇺🇸
Community Health Network, Indianapolis, Indiana, United States
🇺🇸PulmonIx, LLC, Greensboro, North Carolina, United States
🇫🇷Hôpital Bretonneau, Tours, Indre-et-Loire, France
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary FibrosisInterstitial Lung Disease
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 576
- Registration Number
- NCT04708782
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Banner University Medical Center-Phoenix, Phoenix, Arizona, United States
🇺🇸Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States
A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH
- Conditions
- PAHHypertensionPulmonary HypertensionConnective Tissue DiseaseFamilial Primary Pulmonary HypertensionVascular DiseasesCardiovascular DiseasesHypertension, PulmonaryLung DiseasesRespiratory Tract Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT04084678
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇧🇷Centro de Hipertensão Pulmonar, Porto Alegre, Brazil
🇦🇹Ordensklinikum Linz GmbH, Elisabethinen, Linz, Austria